This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human S100B Protein, His Tag
catalog :
S1B-H5143
quantity :
100 ug, 1 mg
price :
250 USD, 1300 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
S1B-H5143
product name :
Human S100B Protein, His Tag
quantity :
100 ug, 1 mg
price :
250 USD, 1300 USD
quantity & price :
$250/100ug,$1300/1mg (500ug × 2)
target :
S100B
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human S100B, His Tag (S1B-H5143) is expressed from E.coli cells. It contains AA Ser 2 - Glu 92 (Accession # NP_006263).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human S100B, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH8.0. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
S-100 protein beta chain (S100B),a member of the S-100 family, is also known as S-100 protein subunit beta and S100 calcium-binding protein B, which contains two EF-hand domains. S100B can weakly bind calcium but bind zinc very tightly-distinct binding sites with different affinities exist for both ions on each monomer. Also, S100B can bind to and initiate the activation of STK38 by releasing autoinhibitory intramolecular interactions within the kinase. Interaction with AGER after myocardial infarction,S100B may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling. Fuethermore,S100B could assist ATAD3A cytoplasmic processing, preventing aggregation and favoring mitochondrial localization. S100B may mediate calcium-dependent regulation on many physiological processes by interacting with other proteins, such as TPR-containing proteins, and modulating their activity.
References :
(1) Yamaguchi F., et al., 2012, J. Biol. Chem. 287:13787-13798.
(2) Smith S.P., et al., 1998, Structure 6:211-222.
(3) McClintock K.A., et al., 2003, J. Biol. Chem. 278:6251-6257.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments